Influenza Vaccines for the World

2-4 April 2019, Royal College of Physicians of Edinburgh, Edinburgh, Scotland, UK

  • Increase font size
  • Default font size
  • Decrease font size

Day Two

Final Conference Programme | Wednesday 3rd April 2019

SESSION 6:
INFLUENZA VACCINES DEVELOPMENTS – III
ANTIGEN DESIGN & CHARACTERIZATION

Moderator: Ted Ross (University of Georgia, Athens, Georgia, USA)

09.00-09.30
‘Re-examining the current polyvalent design of flu vaccines’
Shan Lu (University of Massachusetts, Worcester, Massachusetts, USA)

09.30-09.50
‘The human viral challenge and the evaluation of novel/universal vaccines’
Rob Lambkins-Williams (hVIVO Services Ltd, London, UK)

09.50-10.10
‘Immune engineering: A strategy to couple B cell and T cell immunity for improved pandemic and universal influenza vaccines’
Lenny Moise (EpiVax Inc., Providence, Rhode Island, USA)

10.10-10.30
‘A monoglycosylated universal flu vaccine platform’
J.R. Chen (RuenHuey Biopharamaceuticals Inc., Taiwan)

10.30-10.50
‘Influenza vaccines assessment: Methods and criticals’
Alessandro Torelli (VisMederi Srl, Siena, Italy)

10.50-11.10
Coffee Break & Posters

SESSION 7:
INFLUENZA VACCINES DEVELOPMENTS – IV
MECHANISMS OF ACTION & CORRELATES OF PROTECTION

Moderator: Shan Lu (University of Massachusetts, Worcester, Massachusetts, USA)

11.10-11.40
‘Impact of age and pre-existing immunity on influenza-specific B cells and induction of enhance antibody breadth following vaccination in humans’
Ted M. Ross (University of Georgia, Athens, Georgia, USA)

11.40-12.10
‘New approaches to the development of effective influenza vaccines’
Tokiko Watanabe1 and Yoshihiro Kawaoka2 (1 University of Tokyo, Tokyo, Japan; 2 University of Wisconsin, Madison, Wisconsin, USA)

12.10-12.30
‘IgA is critical for protection against influenza following mucosal delivery’
Nikita Kolhatkar (VAXART Inc, South San Francisco, California, USA)

12.30-12.50
‘Novel live M2SR vaccine elicits broadly cross-reactive immune responses in human subjects’
Pamuk Bilsel (FluGen Inc., Madison, Wisconsin, USA)

12.50-14.00
Lunch Break & Posters

SESSION 8:
INFLUENZA VACCINES DEVELOPMENTS – V
ROUTES OF ADMINISTRATION & ADJUVANTS

Moderator: Dirk Poelart (GSK Vaccines, Wavre, Belgium)

14.00-14.20
‘Micro array patch: Phase I study with influenza vaccine’
Julian Hickling (Vaxxas, Woolloongabba, Brisbane, Australia)

14.20-14.40
‘Improved influenza vaccination through infection mimicry using silk microneedles’

Jonathan Kluge and Kathryn Kosuda (Vaxess Technologies Inc., Cambridge, Massachusetts, USA)

14.40-15.00
‘Microneedle skin vaccination of flagellin-M2e fusion protein and inactivated influenza vaccines confers cross protection’
Baozhong Wang (Georgia State University, Atlanta, Georgia, USA)

15.00-15.20
‘TIV Immunization with a thermostable microneedle patch-immunogenicity and transcriptomics results from a Phase I clinical trial’
Ioanna Skountzou (Emory University, Atlanta, Georgia, USA)

15.20-15.40
Tea Break & Posters

SESSION 9:
CLINICAL DEVELOPMENT OF NEXT-GENERATION INFLUENZA VACCINES

Moderator: Bram Palache (IFPMA/FluPal Consultancy BV, Amstelveen, The Netherlands)

15.40-16.00
‘Update on the clinical development of a plant-derived quadrivalent virus-like particles influenza vaccine’
Nathalie Landry (Medicago Inc., Quebec City, Quebec, Canada)

16.00-16.20
‘Flumist / Fluenz vaccine effectiveness and its return to US market’
Helen Bright (MedImmune UK Ltd, Liverpool, UK)

16.20-16.40
‘Induction of broadly cross-reactive responses against A(H3N2) viruses: Results of a Phase 2 trial of a novel recombinant saponin-adjuvanted seasonal nanoparticle influenza vaccine’
Vivek Shinde, Iksung Cho, Sapeck Agrawal, Rongman Cai, Michelle Spindler, Nigel Thomas, Lou Fries and Greg Glenn (Novavax, Gaithersburg, Maryland, USA)

16.40-17.00
‘Influenza virus-based vector platform for respiratory mucosal vaccination’
Andrey Vasin, Marina Stukova, Andrey Egorov, Maria Sergeeva, Anna-Polina Shurygina, Kirill Vasilev, Janna Buzitskaya and Katya Romanovskaya-Romanko (Research Institute of Influenza, St. Petersburg, Russia)

 

IVW 2019 Delegates

Login details will be supplied after you have registered for the event.


IVW 2019 Sponsors

  • Vaxart
  • Inovio Pharmaceuticals
  • APACI
  • Sanofi Pasteur
  • FluConsult
  • Janssen
  • Medicago
  • hVIVO
  • isirv
  • Novavax
  • SPbSRIVS
  • MedImmune
  • Vaxxas
  • NanoPass
  • BiondVax
  • InDevR
  • Izon Science
  • Eurocine Vaccines
  • Vismederi

IVW 2019 Downloads

IVW 2019 Leaflet

IVW 2019 Mailing List

Name
E-mail Address
What is 3+2-1?